Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cleveland BioLabs (CBLI) stocks in Canada

Learn how to easily invest in Cleveland BioLabs stocks.

Cleveland BioLabs is a biotechnology business based in the US. Cleveland BioLabs stocks (CBLI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 18 staff and has a trailing 12-month revenue of around $106,900.

How to buy shares in Cleveland BioLabs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CBLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cleveland BioLabs stock price (NASDAQ:CBLI)

Use our graph to track the performance of CBLI stocks over time.

Cleveland BioLabs shares at a glance

Information last updated 2021-12-26.
52-week range$2.11 - $10.97
50-day moving average $3.62
200-day moving average $3.62
Wall St. target price$2.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.74

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cleveland BioLabs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cleveland BioLabs price performance over time

Historical closes compared with the close of $N/A from 2021-12-01

1 week (2022-01-10) N/A
1 month (2021-12-17) N/A
3 months (2021-10-21) -100.00%
6 months (2021-07-21) -100.00%
1 year (2021-01-21) -100.00%
2 years (2020-01-21) -100.00%
3 years (2019-01-18) -100.00%
5 years (2017-01-20) -100.00%

Cleveland BioLabs financials

Revenue TTM $106,900
Gross profit TTM $-428,128
Return on assets TTM -20.33%
Return on equity TTM -31.86%
Profit margin 0%
Book value $0.60
Market capitalisation $49.1 million

TTM: trailing 12 months

Cleveland BioLabs share dividends

We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.

Have Cleveland BioLabs's shares ever split?

Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.

Cleveland BioLabs share price volatility

Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $2.11 up to $10.97. A popular way to gauge a stock's volatility is its "beta".

CBLI.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.6837. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).

Cleveland BioLabs overview

Cytocom, Inc. , a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.

Cleveland BioLabs in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site